IVI Releases Non-Small Cell Lung Cancer Patient Qualitative Research
IVI has released the results to their non-small cell lung cancer patient qualitative research, which was used in the development of the structure of upcoming OSVP designed to evaluate lung cancer therapy sequences. According to the research, which was conducted in collaboration with LUNGevity, patients reported valuing treatments that would help increase overall or progression […]
New IVI Research Shows Challenges with ICER Budget Impact Forecasting
IVI research into six pre-2016 ICER studies reveals an overestimation of “unmanaged” drug use and drug cost trends. The peer-reviewed research, published in Value in Health, illustrates the difficulty in predicting budget impact and the consequences of not accounting for uncertainty in value assessment. Read the full article here.
IVI Presents Two Posters at AMCP Nexus 2019
IVI presented two posters at AMCP Nexus 2019, the healthcare conference at the intersection of value and care. In the poster “Understanding Value Through the Patient’s Eyes: Perspectives from Patients with Genetic Mutations in Non-Small Cell Lung Cancer Treatment” researchers show how they examine the perspectives and experiences of patients diagnosed with mNSCLC, and the […]
IVI’s Jeroen Jensen and Devin Incerti write in the Journal of Managed Care and Specialty Pharmacy
IVI’s Lead Scientific Advisor and Lead Economist for the Open-Source Value Platform (OSVP), Jeroen Jansen and Devin Incerti, respectively, collaborate with Jeffery Curtis in a recent article published in the Journal of Managed Care and Specialty Pharmacy about how IVI’s open-source approach to value assessment provides a way to adapt formal assessments of value—long the […]
Rapid Biomedical Innovation Calls for Similar Innovation In Pricing and Value Measurement
Advances in foundational science, technology, and clinical knowledge are driving a revolution in patient care. At the same time, spending on these innovative drugs and devices has increased dramatically. The question is, what—if anything—should be done to regulate this innovation? To balance physician prescribing of state-of-the-art drugs and patient desires to access them with the […]
Relevance of American Society of Clinical Oncology Value Framework Will Be Improved if It Is Based on Network Meta-Analyses
In his letter to the editor, IVI’s Jeroen Jansen makes the case in Journal of Clinical Oncology that network meta-analysis is the only transparent framework to help answer the treatment selection question, and urges the ASCO Value Framework Task Force to consider this approach when developing their recommendations. Source: Journal of Clinical Oncology
Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers.
In the last decade, network meta-analysis of randomized controlled trials has been introduced as an extension of pairwise meta-analysis. The advantage of network meta-analysis over standard pairwise meta-analysis is that it facilitates indirect comparisons of multiple interventions that have not been studied in a head-to-head fashion. Although assumptions underlying pairwise meta-analyses are well understood, those […]
Are Biopharmaceutical Budget Caps Good Public Policy?
Medical innovation has generated significant gains in health over the past decades, but these advances have been accompanied by rapid growth in healthcare spending. Faced with a growing number of high-cost but high impact innovations, some have argued to constrain prices for new therapies – especially through global caps on pharmaceutical spending and limits on […]
Saving Medicare Dollars: Moving from the SGR to Bundled Payments
The goal of Medicare is to provide protection for elderly Americans against the financial risk associated with illness, and in the process provide beneficiaries with access to high quality care. Our challenge is to accomplish those goals in a fiscally sustainable manner. In this article, Michael Chernew, Darius Lakdawalla, and Dana Goldman emphasize that the […]
It’s Time for Value-Based Payment in Oncology
Value-based health care has risen to the top of the health policy agenda, as public and private payers search for ways to improve outcomes. The value principle—reimbursing hospitals, physicians, and other health care providers for quality or quality improvement that also help lower costs—aligns incentives between payers and providers. It’s time to apply this principle […]